Narrative review / 2023
A review outlines the benefits and uncertainties of new weight loss drugs, noting profound caloric reductions may warrant nutritional deficiency testing.
This review evaluates the pros and cons of newer weight loss medications like semaglutide and tirzepatide, noting short-term weight losses of -15% to -20% from baseline. The authors note that profound caloric reductions from these medications should prompt baseline or ongoing nutritional deficiency testing and dietary recommendations. However, long-term adherence, cost, access, supply chain issues, and long-term impacts on mental and physical health remain unknown.
- Study type
- Narrative review
- Who was studied
- Individuals with weight loss and urological conditions
- What was measured
- Advantages and disadvantages of newer weight loss medications (GLP-1 agonists)
THE PAPER
Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).
Moyad MA. Curr Urol Rep, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.